The use of Remdesivir in pregnant women with COVID-19

Gulbanu Shaimerdenova 1 * , Gulzhan Abuova 1, Gaziza Yelshibek 1, Aisholpan Zhuparbek 1, Gulzhanat Bakytzhan 1, Samal Ashtayeva 1, Laura Sarypbekova 1
More Detail
1 Department of Infectious Diseases and Dermatovenerology, South Kazakhstan Medical Academy, Shymkent, Kazakhstan
* Corresponding Author
J CLIN MED KAZ, Volume 20, Issue 1, pp. 31-34. https://doi.org/10.23950/jcmk/12911
OPEN ACCESS 677 Views 438 Downloads
Download Full Text (PDF)

ABSTRACT

Objectives: This study was conducted to investigate the use of Remdesivir among pregnant women with probable and confirmed Covid-19 coronavirus infection.
Material and methods: To implement the study, a comprehensive examination of 120 pregnant women with severe and extremely severe forms of coronavirus infection was conducted.
Results: Statistically significant differences were obtained (p=0.019) at the time of comparison between the main and control groups, depending on the age of the subjects. The studied differences are due to the higher frequency of the age group 33-42 years among patients taking Remdesivir compared to those who were in the control group (p = 0.036). Women of the main group (Me = 9.00; Q1-Q3 = 8.00-11.0) stayed longer in the hospital compared to women in the control group (Me = 8.00; Q1-Q3 = 7.00-10.0). The more severe condition of patients in this group is cause of that. There are statistically significant differences in changes in amniotic fluid according to ultrasound data in the control and main groups (p=0.013). According to the results of our study, it was found that the decrease in temperature to a normal level occurred earlier in the control group (68%) than in the main group.
Conclusion: The older age group and the third trimester of pregnancy are risk factors for the transition to a severe form of the disease. Reliable efficacy of the etiotropic drug Remdesivir could not be traced.

CITATION

Shaimerdenova G, Abuova G, Yelshibek G, Zhuparbek A, Bakytzhan G, Ashtayeva S, et al. The use of Remdesivir in pregnant women with COVID-19. J CLIN MED KAZ. 2023;20(1):31-4. https://doi.org/10.23950/jcmk/12911

REFERENCES

  • Kumar D, Verma S, Mysorekar IU. COVID-19 and pregnancy: clinical outcomes; mechanisms, and vaccine efficacy. Transl Res. 2022; 12:S1931-5244(22)00180-3. https://doi.org/10.1016/j.trsl.2022.08.007
  • https://ourworldindata.org/explorers/coronavirus-data-explorer 07/16/2022
  • Data of the committee for sanitary and epidemiological control of the city of Shymkent, 2022. https://rk-ncph.kz/ru/sanepidem/ezhemesyachnaya-situatsiya
  • Elshafeey F, Magdi R, Hindi N, Elshebiny M, Farrag N, Mahdy S, Sabbour M, Gebril S, Nasser M, Kamel M, Amir A. A systematic scoping review of COVID‐19 during pregnancy and childbirth. International Journal of Gynecology & Obstetrics. 2020;150(1):47-52. https://doi.org/10.1002/ijgo.13182
  • Fan C, Lei D, Fang C, Li C, Wang M, Liu Y, Bao Y, Sun Y, Huang J, Guo Y, Yu Y. Perinatal transmission of 2019 coronavirus Disease–Associated severe acute respiratory syndrome coronavirus 2: should we worry? Clinical Infectious Diseases. 2021;72(5):862-4. https://doi.org/10.1093/cid/ciaa226
  • Yan J, Guo J, Fan C, Juan J, Yu X, Li J, Feng L, Li C, Chen H, Qiao Y, Lei D. Coronavirus disease 2019 in pregnant women: a report based on 116 cases. American journal of obstetrics and gynecology. 2020;223(1):111-e1. https://doi.org/10.1016/j.ajog.2020.04.014
  • Alfaraj S. H., Al-Tawfiq J. A., Memish Z. A. Middle East respiratory syndrome coronavirus (MERS-CoV) infection during pregnancy: reportof two cases and review of the literature. J. Microbiol. Immunol. Infect. 2019; 52(3):501—503. ttps://doi.org/10.1016/j.jmii.2018.04.005
  • Hong L,Smith N.,Keerthy M., Lee-Griffith M.,Garsia R et al. Severe COVID-19 infection in Pregnancy Recuiring Intubation without Preterm Delivery: A Case Report . Case Reports in Womens Health. 2020; 27. https://doi.org/10.1016/j.crwh.2020.e00217
  • Liu D et al. Pregnancy and Perinatal Outcomes of Women With Coronavirus Disease (COVID-19) Pneumonia: A Preliminary Analysis. AJR Am J Roentgenol. 2020; 18:1-6. https://doi.org/10.2214/AJR.20.23072
  • Clinical protocol for the diagnosis and treatment of coronavirus infection COVID-19 in pregnant women, women in labor and puerperas of August 5, 2021. http://www.rcrz.kz/index.php/ru/2017-03-12-10-50-44/press-reliz/2365-press-reliz- 16.07.2022
  • Giniyat A.G., Kulzhanova Sh. A., Tuleshova G.T., Konkayeva M.E., Smagulova Z. K., Beisenbieva N.Ye., Utegenova A.M., Turebaeva G.O., Nurakhmetova G.A., Bolatov A. Clinical efficacy of the antiviral drug remdesivir in the comprehensive treatment of patients with COVID-19. Nauka i Zdravookhranenie [Science & Healthcare]. 2021; 3(23):6-15. https://doi.org/10.34689/SH.2021.23.3.001
  • Shaimerdenova G.G., Abuova G.N. Evaluation of the effectiveness of Remdesivir in pregnant women with Covid-19. Pharmacy. 2022; 5(244):47-53. https://doi.org/10.53511/pharmkaz.2022.79.74.006
  • Vitiello A, Ferrara F, Zovi A, Trama U, Boccellino M. Pregnancy and COVID-19, focus on vaccine and pharmacological treatment. J Reprod Immunol. 2022; 151:103630. https://doi.org/10.1016/j.jri.2022.103630
  • H. Chen, J. Guo, C. Wang, F. Luo, X. Yu, W. Zhang, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020; 395 (10226):809-815. https://doi.org/10.1016/S0140-6736(20)30360-3
  • Shaimerdenova G.G., Abuova G.N., ZhumabekovaS.Zh., KaldybekovaZh.S. Clinic of COVID-19 in pregnant women. Principles of treatment in infectious disease hospitals of Shymkent. Aktualnyeproblemyteoreteticheskoyiklinicheskoymediciny. 2021; 1:59-62.
  • Goldman J.D., Lye D.CB., Hui D.S., Marks K.M., Bruno R. and Montejano R. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020; 383(19):1827-37. https://doi.org/10.1056/NEJMoa2015301
  • S. Mulangu, L.E. Dodd, R.T. Davey Jr., et al., A randomized, controlled trial of Ebola virus disease therapeutics. N. Engl. J. Med. 2019; 381(24):2293–2303. https://doi.org/10.1056/NEJMoa1910993
  • T.I. Hariyanto, F. Kwenandar, K.V. Japar, et al., The effectiveness and safety of remdesivir for the treatment of patients with COVID-19: a systematic review and meta-analysis. Anti-Infect. Agents. 2021; 19(3):333–340. https://doi.org/10.2174/22113533MTEwgNTYp4
  • G.A. Maldarelli, M. Savage, S. Mazur, et al., Remdesivir treatment for severe COVID-19 in third-trimester pregnancy: case report and management discussion. Open Forum Infect. Dis. 2020; 7(9):ofaa345(9).
  • C.D. Spinner, R.L. Gottlieb, G.J. Criner, et al., Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020; 324(11):1048–1057. https://doi.org/10.1001/jama.2020.16349
  • J. Jacobson, K. Antony, M. Beninati, et al., Use of dexamethasone, remdesivir, convalescent plasma and prone positioning in the treatment of severe COVID-19 infection in pregnancy: a case report. Case Rep. Womens Health. 2021; 29(29):e00273. https://doi.org/10.1016/j.crwh.2020.e00273